Omeros submission adds another 2026 catalyst, says H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes keeps a Buy rating on Omeros (OMER) with a $9 price target after the company submitted its marketing authorization to the European Medicines Agency for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. The announcement supports H.C. Wainwright’s view that Omeros shares “may be entering a phase of rerating” over the next 12 months, driven by a potential U.S. approval for narsoplimab, EU approval, and subsequent re-appreciation of the potential in the company’s other pipeline programs, the analyst tells investors in a research note. The firm believes the European submission adds another “significant catalyst” for the stock in 2026. H.C. Wainwright says narsoplimab will be approved in the U.S. and Europe, and will create significant value for Omeros.